| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1007909719 |
| P356 | DOI | 10.1186/S13722-015-0040-7 |
| P932 | PMC publication ID | 4672523 |
| P698 | PubMed publication ID | 26437921 |
| P5875 | ResearchGate publication ID | 282890667 |
| P50 | author | Lehana Thabane | Q28320748 |
| Guillaume Paré | Q30421554 | ||
| David C. Marsh | Q42393440 | ||
| Michael Varenbut | Q115605553 | ||
| P2093 | author name string | Zainab Samaan | |
| Andrew Worster | |||
| Meir Steiner | |||
| Rebecca Anglin | |||
| Brittany B Dennis | |||
| Carolyn Plater | |||
| Dipika Desai | |||
| Jeff Daiter | |||
| Monica Bawor | |||
| Charlie Tan | |||
| P2860 | cites work | Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence | Q24239965 |
| Polysubstance abuse-vulnerability genes: genome scans for association, using 1,004 subjects and 1,494 single-nucleotide polymorphisms | Q24535898 | ||
| Reward deficiency syndrome: a biogenetic model for the diagnosis and treatment of impulsive, addictive, and compulsive behaviors | Q28209521 | ||
| OPRM1 and CYP2B6 Gene Variants as Risk Factors in Methadone-Related Deaths | Q28289166 | ||
| The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function | Q29615582 | ||
| The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies | Q29615686 | ||
| Association between the DRD2 A1 allele and response to methadone and buprenorphine maintenance treatments | Q33238415 | ||
| Evaluation of genetic variability in the dopamine receptor D2 in relation to behavioral inhibition and impulsivity/sensation seeking: an exploratory study with d-amphetamine in healthy participants | Q33889605 | ||
| Contribution of cytochrome P450 and ABCB1 genetic variability on methadone pharmacokinetics, dose requirements, and response | Q33903933 | ||
| Genetic influence on methadone treatment outcomes in patients undergoing methadone maintenance treatment for opioid addiction: a pilot study | Q34109820 | ||
| The burden of premature opioid-related mortality | Q34228368 | ||
| Dopamine and drug addiction: the nucleus accumbens shell connection. | Q34355473 | ||
| Brain-derived neurotrophic factor Val66Met and psychiatric disorders: meta-analysis of case-control studies confirm association to substance-related disorders, eating disorders, and schizophrenia. | Q34600852 | ||
| The BDNF Val66Met polymorphism and plasma brain-derived neurotrophic factor levels in Han Chinese heroin-dependent patients. | Q35035531 | ||
| Nucleus accumbens D2/3 receptors predict trait impulsivity and cocaine reinforcement | Q35844174 | ||
| The genetic basis for smoking behavior: a systematic review and meta-analysis | Q35888652 | ||
| BDNF Val(66)Met genotype is associated with drug-seeking phenotypes in heroin-dependent individuals: a pilot study | Q35987786 | ||
| A meta-analysis of retention in methadone maintenance by dose and dosing strategy | Q36946147 | ||
| Interindividual variability of methadone response: impact of genetic polymorphism | Q37142009 | ||
| Pharmacogenetic treatments for drug addiction: alcohol and opiates. | Q37201611 | ||
| Neurotrophic factors and structural plasticity in addiction | Q37223964 | ||
| Association of genetic variation in pharmacodynamic factors with methadone dose required for effective treatment of opioid addiction | Q37401604 | ||
| Diacetylmorphine versus methadone for the treatment of opioid addiction | Q37452342 | ||
| Impact of ABCB1 and CYP2B6 genetic polymorphisms on methadone metabolism, dose and treatment response in patients with opioid addiction: a systematic review and meta-analysis | Q38184547 | ||
| The role of opioidergic genes in the treatment outcome of drug addiction pharmacotherapy: A systematic review | Q38270731 | ||
| Methadone-maintenance outcomes for Hispanic and African-American men and women | Q39490487 | ||
| Polymorphisms of brain-derived neurotrophic factor associated with heroin dependence | Q39764792 | ||
| Prognostic factors in Buprenorphine- versus methadone-maintained patients | Q42545202 | ||
| Vulnerability to substance abuse and psychopathology among siblings of opioid abusers | Q43996191 | ||
| Genetic variation in dopamine pathways differentially associated with smoking progression in adolescence. | Q44048254 | ||
| The D(2) dopamine receptor A(1) allele and opioid dependence: association with heroin use and response to methadone treatment | Q44333574 | ||
| BDNF variability in opioid addicts and response to methadone treatment: preliminary findings. | Q44337437 | ||
| Association of dopamine and opioid receptor genetic polymorphisms with response to methadone maintenance treatment | Q44339701 | ||
| Males and females differ in response to opioid agonist medications | Q44349678 | ||
| Association study between brain-derived neurotrophic factor gene polymorphisms and methamphetamine abusers in Japan. | Q45087047 | ||
| Cannabis use, abuse, and dependence in a population-based sample of female twins | Q45113019 | ||
| Cocaine use, abuse and dependence in a population-based sample of female twins | Q45116057 | ||
| Genetic variants altering dopamine D2 receptor expression or function modulate the risk of opiate addiction and the dosage requirements of methadone substitution | Q46047802 | ||
| Brain-derived neurotrophic factor (Val66Met) genetic polymorphism is associated with substance abuse in males | Q46657920 | ||
| Significant association of BDNF haplotypes in European-American male smokers but not in European-American female or African-American smokers. | Q46694313 | ||
| Association of the met66 allele of brain-derived neurotrophic factor (BDNF) with smoking | Q48329466 | ||
| DRD2 genetic variation in relation to smoking and obesity in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial | Q48424021 | ||
| Psychiatric disorders in relatives of probands with opiate addiction. | Q52053178 | ||
| An adoption study of genetic and environmental factors in drug abuse. | Q52077065 | ||
| Chronic heroin and cocaine abuse is associated with decreased serum concentrations of the nerve growth factor and brain-derived neurotrophic factor. | Q52291688 | ||
| Analysis of dopamine D2 receptor (DRD2) gene polymorphisms in cannabinoid addicts. | Q52300747 | ||
| Impact of genetic polymorphisms in ABCB1, CYP2B6, OPRM1, ANKK1 and DRD2 genes on methadone therapy in Han Chinese patients. | Q54562217 | ||
| Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment | Q57550282 | ||
| Cytochrome P450 2D6 Genotype and Methadone Steady-State Concentrations | Q57550363 | ||
| Familial Transmission of Substance Use Disorders | Q58564475 | ||
| Brain-derived neurotrophic factor serum concentrations are increased in drug-naïve schizophrenic patients with chronic cannabis abuse and multiple substance abuse | Q60640489 | ||
| Heterogeneity in the inheritance of alcoholism. A study of male and female twins | Q68176961 | ||
| Heritability of substance abuse and antisocial behavior: a study of monozygotic twins reared apart | Q68840008 | ||
| Adoption study demonstrating two genetic pathways to drug abuse | Q72384265 | ||
| CYP2B6 and OPRM1 gene variations predict methadone-related deaths | Q82886892 | ||
| The role of opioidergic genes in the treatment outcome of drug addiction pharmacotherapy: A systematic review | Q87020286 | ||
| Association of the DRD2 gene Taq1A polymorphism and alcoholism: a meta-analysis of case-control studies and evidence of publication bias | Q95825809 | ||
| P921 | main subject | opioid | Q427523 |
| opioid use disorder | Q1639178 | ||
| substance use disorder | Q7632070 | ||
| P304 | page(s) | 19 | |
| P577 | publication date | 2015-10-06 | |
| P1433 | published in | Addiction Science and Clinical Practice | Q15758238 |
| P1476 | title | Contribution of BDNF and DRD2 genetic polymorphisms to continued opioid use in patients receiving methadone treatment for opioid use disorder: an observational study | |
| P478 | volume | 10 |
| Q92210407 | Decreased Level of Blood MicroRNA-133b in Men with Opioid Use Disorder on Methadone Maintenance Therapy |
| Q91775826 | Four single nucleotide polymorphisms in genes involved in neuronal signaling are associated with Opioid Use Disorder in West Virginia |
| Q47425192 | Pharmacogenetics of Methadone Response |
| Q88289080 | Pharmacogenetics of Opioid Use Disorder Treatment |
| Q37223916 | Relationship among methadone dose, polymorphisms of dopamine D2 receptor and tri-dimensional personality questionnaire in heroin-addicted patients |
Search more.